Mandate

Vinge advises the Swedish National Debt Office in connection with a state credit guarantee for SAAB

February 24, 2010

Vinge has represented the Swedish government acting through the Swedish National Debt Office in connection with the state credit guarantee for SAAB Automobile’s loan of EUR 400 million from the European Investment Bank (EIB). The state guarantee agreement was entered into in conjunction with closing of Spiker Cars N.V.’s acquisition of all shares in SAAB. Saab and its new owners have provided pledges in various assets in Sweden as security for their obligations in accordance with the back-to-back agreement which Saab has entered into with the National Debt Office.

Vinge’s team included partners Maria-Pia Midenbäck Hope (responsible partner), Carl Gustav De Geer, Fabian Ekeblad and Per Eric Alvsing and associates Dan Hanqvist, Louise Brorsson Salomon, Nils Taro-Lock, Christina Olsson Rosén, Tina Hård and Sofia Berg as well as project assistant Bettina Gamba.

Related

Vinge advises OsteoCentric on the public offer for Integrum

OsteoCentric Oncology and Bone Anchored Prostheses, LLC, a subsidiary of OsteoCentric Technologies, Inc., has made a public offer for all shares in Integrum AB (publ). The offer values all shares in Integrum at approximately SEK 939 million.
July 23, 2025

Vinge advises Investor on its co-investment in the SEK 55 billion public offer for Fortnox led by EQT X

Vinge advises Investor AB (publ) (“Investor”) on its co-investment in the public offer for Fortnox AB (publ) (“Fortnox”) led by EQT X together with First Kraft AB (owned by Olof Hallrup), acting through Omega II AB (“Omega II”). Fortnox offers vital software infrastructure to small and medium-sized companies in Sweden with a track record of profitable growth.
July 22, 2025

Vinge advises Cantargia in connection with the sale of immunology program CAN10

Vinge advises Cantargia AB (publ) in connection with the sale of its early-clinical stage IL1RAP immunology program CAN10 to the Japanese healthcare company Otsuka Pharmaceutical.
July 21, 2025